The size of the global preclinical CRO market was worth USD 4.12 billion in 2023 and is estimated to grow at a CAGR of 8.3% from 2024 to 2029 and be worth USD 6.65 bn by 2029 from USD 4.46 billion in 2024.
Preclinical CRO produces a pharmaceutical item or medical equipment from the planning stages to treatment. It involves researchers, specialists, a healthy workforce, legislative and industry contacts, and other specialized innovative people. Before human clinical trials, the medicine must pass the preclinical preliminaries to ensure it is safe for human trials. Preclinical research is of prime importance and has various risks associated with it. It is the phase where there is a high chance that a product might fail, hence choosing a CRO. The preclinical CRO is vital in bringing a concept to the store for various biopharmaceutical organizations.
Global Preclinical CRO Market Drivers:
The latest interest of key market players in the field is supporting the preclinical CRO market growth. There has been continuous growth in the market due to the growing investments from key market players. For example, Albert Labs International Corp. signs a Letter of Intent (LOI) with a full-service Contract-Research Organization (CRO), iNGEN, to conduct the Company's first-in-human study of its leading drug target, KRN-101. Albert Labs International Corp. is a pharmaceutical drug development company focused on obtaining regulatory approval for novel medications to treat various mental health conditions. And RespireRx Pharmaceuticals Inc., a pioneer in the development of novel and ground-breaking therapies to treat illnesses brought on by disruption of neuronal signaling, is happy to announce that on November 14, 2022, the Company signed a letter of intent ("LOI") with a specialized clinical research organization with Australian headquarters that specializes in cannabinoid and psychedelic clinical research.
Global Preclinical CRO Market Restraints:
The regulations by animal rights protectors and animal testing restrictions are the major factors restraining the global market. For instance, in Europe, animal-based products or medicines are banned. Moreover, the rise in adopting alternative methods, such as micro-dosing hinders market growth. The preclinical CROs do not comply with international regulatory requirements like Good Laboratory Practice (GLP) standards, leading to quality issues, which is a major market challenge.
Impact of COVID-19 on the global preclinical CRO market:
COVID has affected all sectors in a significant way. Due to the coronavirus outbreak, the WHO has suggested all countries for a strict lockdown. More than 230 countries have implemented lockdowns, and all the companies and industries are closed, which has affected the world economy. The market has registered some losses during the pandemic. The pharmaceutical industries and medical device companies have paused the new trials due to strict lockdown regulations. The R&D investments for preclinical and clinical trials of the medicines are decreased. The pandemic led to a shift of focus from all other clinical research to vaccine development leading to significant losses for preclinical CROs. However, the market's key players are trying their best by investing in R&D to sustain the market competition.
REPORT COVERAGE:
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Analysed |
By Service Type, By End User |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
Key Market Players |
Charles River Laboratories International, Inc., Laboratory Corporation of America, Envigo, Eurofins Scientific, PRA Health Science, Inc., Wuxi AppTec, Medpace, Inc., Pharmaceutical Product Development, LLC and Paraxel International Corporation. |
This research report on the global preclinical CRO market has been segmented and sub-segmented based on service type, end-user, and region.
Global Preclinical CRO Market - By Service Type:
Toxicology testing holds the largest market share in the preclinical CRO market based on service type. The rise in demand for new drugs and chemicals is boosting the market. Moreover, the growth in the outsourcing of non-core preclinical CRO studies and the adoption of toxicology tests fuel the market.
Global Preclinical CRO Market - By End-user:
Based on end-user, Biopharmaceutical companies are the most significant end-user segment for preclinical CRO. The rise in outsourcing end-to-end services for pharmaceutical companies, primarily for small and mid-size companies, escalates the market's growth rate. In addition, the growth in drug entities based on rising competition has fuelled the market.
Global Preclinical CRO Market - By Region:
Geographically, North America dominated the preclinical CRO market in 2023 and the lead of the North American region in the global market is anticipated to continue throughout the forecast period. The presence of a massive number of preclinical market players is the main reason North America's market growth. The key North American market contributors by the United States and Canada. According to ClinicalTrail.gov, In 2020, approximately 45,400 preclinical studies were registered only in the United States. Further, pharmaceutical companies are interested in novel drug development for better treatment of chronic diseases, leading to North American market growth.
Asia-Pacific is predominantly rising during the forecast period. As a result, the size of the Asia Pacific preclinical CRO market was valued at USD 0.7 billion in 2020 and is estimated to be growing at a CAGR of 8.59%, reaching USD 1.06 billion by 2025 during the forecast period 2020-2025. India, China, and Japan are leading countries contributing to the Asia Pacific market share. The presence of numerous pharmaceutical companies in countries like India and China is the primary factor for market growth. Moreover, the increase in R&D investments and the secure government policies propels the Asia Pacific preclinical CRO market.
KEY MARKET PARTICIPANTS:
Some of the major companies dominating the global preclinical CRO market profiled in the report are Charles River Laboratories International, Inc., Laboratory Corporation of America, Envigo, Eurofins Scientific, PRA Health Science, Inc., Wuxi AppTec, Medpace, Inc., Pharmaceutical Product Development, LLC and Paraxel International Corporation.
SOME OF THE RECENT HAPPENINGS IN THIS MARKET:
FAQ's
As per our research report, the global preclinical CRO market size is projected to be USD 6.14 billion by 2028.
The global preclinical CRO market is estimated to grow at a CAGR of 8.3% from 2023 to 2028.
Geographically, the APAC preclinical CRO market is predicted to have the fastest growth rate in the global market from 2023 to 2028.
Charles River Laboratories International, Inc., Laboratory Corporation of America, Envigo, Eurofins Scientific, PRA Health Science, Inc., Wuxi AppTec, and Medpace, Inc. are some of the key players operating the preclinical CRO market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]